TauRx Therapeutics Achieves Enrollment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease. This multi-centre, placebo-controlled clinical trial (Protocol TRx-237-005) is aimed at assessing the efficacy of LMTX™ in people diagnosed with mild Alzheimer’s disease. The study is also evaluating the safety and pharmacokinetic profile of LMTX™, and incorporates imaging endpoints in all subjects.